Pharmacolog signs a collaboration agreement with researchers at Uppsala University regarding antibiotic treatment

Pharmacolog AB has entered a research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood during treatment of patients with severe infections.

Antibiotic treatment with the right dose is crucial for patients to survive severe infections. Today, technology is lacking to quickly determine blood concentrations of antibiotics in patients treated for serious infections. The collaboration between Pharmacolog AB and Professor Miklos Lipcsey at the Department of Surgical Sciences and Professor Anders Larsson at the Department of Medical Sciences, both at Uppsala University, is a result of preparatory tests of the ability to measure the antibiotic concentration in blood with Pharmacolog’s current technology. The collaboration will continue until December 2017 with the aim of developing a method for rapidly and patiently determining blood levels of antibiotics in patients treated for severe infections.

Hans Dahlin, Founder and Research Director at Pharmacolog: “I am extremely pleased that after a time of preliminary tests we can start this important research project with two outstanding experts on antibiotic treatment of severe infections. The project is well within our vision of participating in research projects that can lead to the development of new products for patient-controlled controls of intravenous drug treatments of severe diseases such as sepsis and cancer.”

Dr. Miklos Lipcsey, anesthetist and researcher Academic Hospital: “Healthcare is facing major challenges regarding the use of antibiotics. The correct dose is necessary to cure difficult infections but also a prerequisite for preventing resistance development. The research collaboration with Pharmacolog is very interesting given the great need for rapid analysis and measures in the treatment of antibiotics in severe infections. Several studies have shown that delayed or insufficient initial antibiotic treatment leads to significantly increased mortality in sepsis. We have already received some interesting promising results that we now hope through this project will result in scientific work that can contribute to new products for safer and more patient-adapted antibiotic treatment.”

 

DrugLog® will be evaluated by a hospital chain in New York

Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.

Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in usi...

Nyemissionen registrerad

Pharmacolog i Uppsala AB (publ) har genomfört en nyemission med företrädesrätt för befintliga aktieägare med teckningstid 27 september – 13 oktober 2017 efter beslut av styrelsen den 28 augusti med stöd av bemyndigande från Bolagets årsstämma den 3 maj 2017. Emissionen, som övertecknades, tillförde Bolaget 19,6 MSEK före emissionskostnader.

Emissionen har registrerats av Bolagsverket den 1 november 2017. I samband med att emissionen har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA) att avregistreras och ersättas av nya aktier. Sista dag för handel med BTA på Aktietorget är den 6 november 2017.

Genom nyemissionen har aktiekapitalet i Pharmacolog ökat med 1 178 799,90 SEK...

Företrädesemissionen övertecknades till 150%

Teckningsperioden för Pharmacologs företrädesemission löpte ut den 13 oktober 2017 och det slutliga utfallet visar att den tecknades till 89,35 procent med stöd av teckningsrätter. Resterande del, motsvarande 10,65 procent, har tecknats utan stöd av teckningsrätter. Företrädesemissionen är därmed fulltecknad och tillför Bolaget cirka 19,6 MSEK före emissionskostnader. Sammanlagt tecknades Företrädesemissionen till drygt 150 procent.

Totalt tecknades 3 510 991 aktier med stöd av teckningsrätter, motsvarande cirka 17,6 MSEK eller 89,35 procent av Företrädesemissionen. Resterande 418 342 aktier, motsvarande cirka 2,1 MSEK eller 10,65 procent av Företrädesemissionen, har tilldelats personer som teckn...

New analysis of Pharmacolog

New company analysis of Pharmacolog AB performed by Jarl Securities. Read the complete analysis here (in Swedish only): https://www.aktiespararna.se/sites/default/files/phlog_2017-09-28.pdf